论文部分内容阅读
目的:探讨瑞舒伐他汀联合丹参酮对老年心力衰竭患者血清核转录因子kappa B(NF-κB)和白细胞介素-1β(IL-1β)水平的影响。方法:选择2011年7月~2015年7月于我院进行治疗的老年心力衰竭患者68例,按照电脑生成的随机数字表将所有患者随机分为实验组和对照组,每组各34例,对照组使用瑞舒伐他汀进行治疗,实验组患者在对照组的治疗基础上加用丹参酮进行治疗,对比分析两组患者血清核因子-κB(NF-κB)、白细胞介素-1β(IL-1β)、超敏C反应蛋白(hs-CRP)、一氧化氮(NO)、内皮素-1(ET-1)及B型钠尿肽(BNP)水平,并对两组患者的临床疗效进行评价。结果:与治疗前相比,治疗后两组患者血清NF-κB、IL-1β,ET-1、BNP及hs-CRP水平均降低,血清NO水平均升高(P<0.05),且与对照组相比,实验组患者血清NF-κB、IL-1β、hs-CRP、ET-1及BNP水平较低,NO水平及临床总有效率较高(P<0.05)。结论:瑞舒伐他汀联合丹参酮对老年心力衰竭具有很好的治疗效果,推测其机制与降低血清NF-κB、IL-1β、hs-CRP、ET-1及BNP水平及升高NO水平有关。
Objective: To investigate the effect of rosuvastatin combined with tanshinone on the levels of serum nuclear factor kappa B (NF-κB) and interleukin-1β (IL-1β) in elderly patients with heart failure. Methods: Seventy-eight elderly patients with heart failure who were treated in our hospital from July 2011 to July 2015 were randomly divided into experimental group and control group according to random number table generated by computer, 34 cases in each group, The control group was treated with rosuvastatin. The patients in the experimental group were treated with tanshinone on the basis of the control group. The levels of serum NF-κB, IL- 1β, hs-CRP, NO, ET-1 and B-type natriuretic peptide (BNP) Evaluation. Results: Compared with those before treatment, the serum levels of NF-κB, IL-1β, ET-1, BNP and hs-CRP were decreased and the serum NO levels were higher in the two groups (P <0.05) Compared with the control group, the serum levels of NF-κB, IL-1β, hs-CRP, ET-1 and BNP in the experimental group were lower, and the levels of NO and clinical total effective rate were higher (P <0.05). Conclusions: Rosuvastatin combined with tanshinone has a good therapeutic effect on heart failure in elderly patients. It is speculated that the mechanism may be related to the decrease of serum levels of NF-κB, IL-1β, hs-CRP, ET-1 and BNP as well as NO.